» Portfolio News

03.10.17

NOXXON veröffentlicht präklinische Daten zur Wirksamkeit (Proof of Concept) des Lead-Produktes NOX-A12 in Kombination mit Checkpoint-Inhibitoren

Weiterlesen...

29.09.17

NOXXONS Aufsichtsrat wählt erfahrenen US & EU Biotech-Veteranen Don deBethizy zum Vorsitzenden

Weiterlesen...

28.09.17

NOXXON veröffentlicht Update zur laufenden klinischen Phase 1/2 Studie mit dem Lead-Programm NOX-A12

Weiterlesen...

18.07.17

NOXXON Pharma gibt erste Tranche von Odirnane-Wandelschuld-verschreibungen aus 

Weiterlesen...

11.07.17

NOXXON gibt Prospektveröffentlichung und Transfer der Aktien in das öffentliche Handelssegment des Euronext Growth bekannt

Weiterlesen...

04.01.17 - NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion


NOXXON continues transition to clincal oncology company

 


Berlin, Germany, January 04, 2017 - NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on cancer treatment, has today announced an agreement with Aptarion biotech AG to license enabling technology, assign certain preclinical and technology research programs and transfer lab assets in exchange for cash, royalties and an equity stake in Aptarion.

 

 

NOXXON has maintained exclusive rights to Spiegelmers binding to the targets of its clinical-stage programs. Otherwise, the agreement allows both companies to use the Spiegelmer® technology, and a cross-licensing provision provides for continued access to new enabling inventions to be used by both companies.

 

 

“This agreement is another step on the transition of NOXXON to a clinical-stage oncology company. With our focus on clinical development of our programs in oncology, we made the decision to spin-out the other assets and this agreement with Aptarion is, we believe, the best opportunity to see them successfully developed.” commented Aram Mangasarian, CEO of NOXXON.